Modality
Multispecific
MOA
Cl18.2
Target
SHP2
Pathway
Amyloid
AngelmanFabryGastric Ca
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
~Feb 2019
→ ~May 2020
Phase 2
~Aug 2020
→ ~Nov 2021
Phase 3
~Feb 2022
→ ~May 2023
NDA/BLA
~Aug 2023
→ ~Nov 2024
Approved
Feb 2025
→ Apr 2025
ApprovedCurrent
NCT04618550
1,437 pts·Gastric Ca
2025-02→TBD·Active
NCT05337102
2,019 pts·Fabry
2025-11→2025-04·Terminated
3,456 total pts2 indications
CompletedCurrentUpcoming
Catalysts (1)
2025-04-0512mo agoPh3 Readout· Fabry
Trial Timeline
Q2Q3Q4
Approved
Active
Approved
Termina…
Catalysts
Ph3 Readout
2025-04-05 · 12mo ago
Fabry
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04618550 | Approved | Gastric Ca | Active | 1437 | EASI-75 |
| NCT05337102 | Approved | Fabry | Terminated | 2019 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| 180-3597 | Innovent Bio | Preclinical | SHP2 |